Trump announces trade deal with EU following months of negotiations
Investing.com - UBS raised its price target on Boston Scientific (NYSE:BSX) to $135.00 from $130.00 while maintaining a Buy rating, citing the company’s strong product cycle and sales performance. The medical device maker, currently trading near its 52-week high of $108.94, has delivered an impressive 20.64% return year-to-date, according to InvestingPro data.
The medical device maker exceeded expectations with organic sales and earnings per share growth surpassing both UBS and consensus estimates, demonstrating sustained and building momentum across new product launches. With a robust gross margin of 68.45% and revenue growth of 19.36%, Boston Scientific’s financial performance reflects its strong market position.
Boston Scientific’s FARAPULSE product notably supported electrophysiology growth of 94% on a worldwide organic basis, while the Agent DCB and LAAC franchise returned to more than 25% worldwide organic growth for the first time since the second quarter of 2023, driven by positive data and indication expansion.
The company now expects a reduced tariff impact of $100 million, down from the $200 million previously anticipated, which UBS believes can be more than offset by operational performance, foreign exchange tailwinds, and reduced discretionary spending.
Despite Boston Scientific being one of the more crowded long positions within UBS’s coverage universe, the firm maintains its Buy rating based on the company’s continued operational strength and the breadth of its product portfolio, including FARAPULSE, WATCHMAN, Agent DCB, and an upcoming positive CRM product cycle. InvestingPro analysis indicates the stock is trading above its Fair Value, with 14+ additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Boston Scientific reported impressive second-quarter 2025 earnings, surpassing analysts’ expectations. The company achieved an adjusted earnings per share (EPS) of $0.75, exceeding the forecast of $0.73. Revenue also outperformed projections, reaching $5.06 billion compared to the anticipated $4.89 billion. This strong financial performance was bolstered by a 17.4% organic growth in sales, driven by the momentum in their Pulse Field Ablation (PFA) technology and increased adoption of the Watchman device. Wells Fargo (NYSE:WFC) responded by raising its price target for Boston Scientific to $124, maintaining an Overweight rating, citing the growth in PFA technology as a key factor. Similarly, BofA Securities increased its price target to $120, keeping a Buy rating, despite noting a $100 million impact on the adjusted income statement. These developments highlight the company’s strong position in the market and its promising technological advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.